EGFR and metastatic neoplasm: All received single-agent PD-1 blockade with 37 (61%) in the first-line (1L) setting for advanced, incurable or metastatic disease and 24 (39%) in the second-line (2L) setting after chemotherapy and/or epidermal growth factor receptor (EGFR) inhibitor therapy use in the 1L.